Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update
BRISBANE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediat...
What are the implications of the Q2 results for Tempest's long‑term growth strategy and valuation?
What is the market's reaction to the earnings release and business update on social and institutional platforms?
Are there any notable changes in operating expenses or R&D spending that could affect future profitability?
26 days ago